BioSpace News Archive

Surgalign Holdings, Inc. announced that it has granted restricted stock unit awards to one employee, who was not an executive officer, as an inducement for them to accept employment with Surgalign, and representing the right to receive, in the aggregate, up to 9,259 shares of Surgalign common stock.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, announced that it has granted a non-statutory share option to purchase an aggregate of 10,000 ordinary shares of the Company as an inducement to a newly hired employee.

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its third quarter of fiscal 2022, ended May 31, 2022.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced its membership in the Corporate Council of the Pediatric Dermatology Research Alliance.

Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted three employees nonqualified stock options to purchase an aggregate of 24,500 shares of its common stock with an exercise price of $9.29 per share, which is equal to the closing price of Kezar’s common stock on July 1, 2022.

Cell expansion market is expected to gain market growth in the forecast period of 2022 to 2029.

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on July 1, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 30,875 shares of Puma common stock to six new non-executive employees.

To understand the analysis and the chronic lymphocytic leukemia therapeutics market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Agile Therapeutics, Inc., a women’s healthcare company, announced the closing of its previously announced upsized public offering of an aggregate of 26,666,666 shares of its common stock, together with accompanying common stock warrants, at a public offering price of $0.90 per share and accompanying warrants.

The scope of an exceptional Advanced Therapy Medicinal Products market report can be expanded from market scenarios to comparative pricing between major players.